Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk factors in rheumatoid arthritis
A paper published in Clinical Rheumatology from the research group of our Scientific Officer Manuel Castro Cabezas and Chief Scientific Officer Rick Grobbee indicates that patients with rheumatoid arthritis with high liver fibrosis scores are likely to have a higher risk of cardiovascular events. Incorporating fibrosis measurements into routine clinical care for rheumatoid arthritis patients could identify individuals with highest risk and enable risk management strategies.
Read more here or reach out to our experts if you have any questions.
Related
ESC 2026 Takeaways: Precision Prevention, Smarter Risk Assessment, and the Evolving Future of Cardiovascular Trials
The P95 Julius Clinical team recently joined researchers, sponsors, clinicians, and industry leaders in Munich for ESC Congress 2026. Across scientific sessions, new clinical guidance, and industry discussions, several themes emerged that could in...
Fact Sheet: Cardiometabolic Clinical Development
A Science-Led CRO Partner for Complex Cardiometabolic Clinical Trials Cardiometabolic diseases rarely occur in isolation. Obesity, diabetes, cardiovascular disease, chronic kidney disease, lipid disorders, and metabolic liver disease share interc...
Beyond Weight Loss: Why the Next Phase of Cardiometabolic Innovation Will Be Defined by Outcomes
With obesity affecting more than one billion people globally and the market for obesity therapeutics projected to grow dramatically over the next decade, the stakes for sponsors have never been higher. Driven by breakthrough therapies, rapid marke...
